Table 2: Prognostic factors in cytoreductive surgery for isolated lymph node relapsing.
Authors | Ferrero, et al. [31] | Fotiu, et al. [29] | Santillan, et al. [33] | Uzan, et al. [32] |
Patients | 73 | 21 | 25 | 12 |
Mean age: Years | 54 | 52 | 55 | 51 |
DFI: Months | 18 | 21 | 16 | 21 |
Pre/post-SCS treatment | ||||
Chemotherapy | 70 | 1 | 1 | 9 |
Radiotherapy | 0 | 4 | 4 | 15 |
Chemotherapy + radiotherapy | 0 | 3 | 1 | 17 |
None | 3 | 0 | 2 | 1 |
PFS after relapsing: Months | 46 | 21 | 10 | 44 |
OS after relapsing: Months | 60 (64%) | 60 (68%) | 37 | 60 (71%) |
DFI: Disease free interval; PFS: Progression free survival; OS: Overall survival; SCS: Secondary cytoreductive surgery.